

## Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France

Clément Ferrier, Babak Khoshnood, Ferdinand Dhombres, Hanitra Randrianaivo, Isabelle Perthus, Jean-Marie Jouannic, Isabelle Durand-Zaleski

### ▶ To cite this version:

Clément Ferrier, Babak Khoshnood, Ferdinand Dhombres, Hanitra Randrianaivo, Isabelle Perthus, et al.. Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France. BMJ Open, 2020, 10 (7), pp.e036566. 10.1136/bmjopen-2019-036566 . hal-03229519

## HAL Id: hal-03229519 https://hal.sorbonne-universite.fr/hal-03229519v1

Submitted on 19 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **BMJ Open** Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France

Clément Ferrier,<sup>1</sup> Babak Khoshnood <sup>()</sup>,<sup>2</sup> Ferdinand Dhombres,<sup>1</sup> Hanitra Randrianaivo,<sup>3</sup> Isabelle Perthus,<sup>4</sup> Jean-Marie Jouannic <sup>()</sup>,<sup>5</sup> Isabelle Durand-Zaleski<sup>6</sup>

#### ABSTRACT

**Objective** To assess trends in the average costs and effectiveness of the French ultrasound screening programme for birth defects.

**Design** A population-based study.

**Setting** National Public Health Insurance claim database. **Participants** All pregnant women in the 'Echantillon Généraliste des Bénéficiaires', a permanent representative sample of 1/97 of the individuals covered by the French Health Insurance System.

Main outcomes measures Trends in the costs and in the average cost-effectiveness ratio (ACER) of the screening programme (in  $\in$  per case detected antenatally), per year, between 2006 and 2014. incremental costeffectiveness ratio (ICER) from 1 year to another were also estimated. We assessed costs related to the ultrasound screening programme of birth defects excluding the specific screening of Down's syndrome. The outcome for effectiveness was the prenatal detection rate of birth defects, assessed in a previous study. Linear and logistic regressions were used to analyse time trends. **Results** During the study period, there was a slight decrease in prenatal detection rates (from 58.2% in 2006 to 55.2% in 2014; p=0.015). The cost of ultrasound screening increased from €168 in 2006 to €258 per pregnancy in 2014 (p=0.001). We found a 61% increase in the ACER for ultrasound screening during the study period. ACERs increased from €9050 per case detected in 2006 to  $\in$ 14 580 per case detected in 2014 (p=0.001). ICERs had an erratic pattern, with a strong tendency to show that any increment in the cost of screening was highly cost ineffective.

**Conclusion** Even if the increase in costs may be partly justified, we observed a diminishing returns for costs associated with the prenatal ultrasound screening of birth defects, in France, between 2006 and 2014.

#### INTRODUCTION

Screening and prevention are not necessarily cost saving or more cost effective than treatment for existing conditions. A review of the cost-effectiveness literature found that 'distributions of cost-effectiveness ratios

#### Strengths and limitations of this study

- We observed the chronological trend of the average cost-effectiveness ratio of the French ultrasound birth defect screening programme.
- We used two large data sources: national registries of birth defect and the national claims database.
- Almost all costs related to the screening were included.
- We used a unique effectiveness criterion: the prenatal detection rate of birth defects.
- Costs and prenatal detection rates had to be extrapolated from different samples because nationwide data are not available in France.

for preventive measures and treatments are very similar—in other words, opportunities for efficient investment in healthcare programmes are roughly equal for prevention and treatment'.<sup>1</sup>

Screening and prevention can reduce morbidity and morbidity by allowing earlier diagnosis; however, this would not necessarily reduce costs if only a small part of the population targeted for prevention is at risk to be affected by a disease or in the absence of treatment. Screening a large population requires important resources, which may be better used to support other healthcare actions.<sup>2</sup>

All industrialised countries organise programmes for prenatal birth defects screening.<sup>3</sup> Indeed, congenital abnormalities represent one of the leading cause of infant mortality, morbidity and long-term adverse developmental outcomes.<sup>4–6</sup>

So far, medico economic studies of prenatal screening for congenital anomalies have mostly focused on Down's syndrome screening. Studies of prenatal screening for structural fetal anomalies are rare. Several reviews<sup>7 8</sup> have highlighted the limits of the

**To cite:** Ferrier C, Khoshnood B, Dhombres F, *et al.* Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France. *BMJ Open* 2020;**10**:e036566. doi:10.1136/ bmjopen-2019-036566

Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/bmjopen-2019-036566).

Received 23 December 2019 Revised 13 May 2020 Accepted 09 June 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

#### **Correspondence to**

Dr Isabelle Durand-Zaleski; isabelle.durand-zaleski@aphp.fr



current literature on the subject, whether in comparisons of different modalities of screening<sup>9 10</sup> or screening versus no screening.<sup>11 12</sup> Moreover, while screening programmes for birth defects are organised in all industrialised countries, the cost-effectiveness (using global costs and prenatal detection rates) of such programmes was never evaluated at a national level. The available data in France suggest that detection rates of birth defects remain stable since the early 2000.<sup>13 14</sup>

Using national cost claims data and registry-based prenatal detection rates, our objective was to assess trends in the costs and effectiveness (cost per birth defect detected) of the French ultrasound screening programme for birth defects, by estimating both annual average cost-effectiveness ratio (ACER) and incremental cost-effectiveness ratio (ICER) from 1 year to another.

#### DATA AND METHODS

We assessed time trends for costs, efficacy and ACER of the French ultrasound screening programme for structural birth defects, between 2006 and 2014. In France, three ultrasound screening examinations are recommended for singleton pregnancies at 11-14, 20-25 and 30–35 weeks of gestation.<sup>15</sup> A screening for birth defects is performed during these examinations, in addition to other analysis (placenta localisation, fetal growth estimation). The scans are performed by certified practitioners and examinations' reports must include images of standard views following the French guidelines.<sup>15</sup> Both public and private centres must comply with these guidelines. When a fetal anomaly is suspected, further examinations are performed by specialists and the parents are referred to prenatal referral centres.<sup>16</sup> There are 48 referral centres for prenatal diagnosis in France and its overseas territories, providing full diagnostic workup, parents counselling and fetal treatments. When a severe fetal anomaly is confirmed, termination of pregnancy for fetal abnormality (TOPFA) can be authorised, regardless of the gestational age, according to the French regulations.<sup>17</sup> TOFPA may be considered at the request of the parents, if the continuation of the pregnancy seriously endangers the mother's health, or if there is a high probability for the future born infant to be affected by a severe and incurable disease. In addition to ultrasound screening examinations, a first trimester combined test is offered to all pregnant women for the evaluation of the risk of Down's syndrome. This combined testing is based on maternal age, maternal biochemical markers and nuchal translucency measurement.<sup>18</sup>

The outcome for effectiveness was the prenatal detection rate of fetuses with birth defects. Details of the methodology for data sources, definition of cases, exclusion criteria, in particular for cases detected by other modalities than ultrasound and calculation methods have been reported elsewhere.<sup>13</sup> The prenatal detection rate was defined as the ratio of the number of cases detected prenatally (positive screening) on the total number of cases per year. A case was defined as a fetus with at least one abnormality whatever the pregnancy outcome was (live birth or fetal loss after 20 WG or following a TOFPA). The screening was considered positive if the fetal anomaly was suspected by ultrasound during the pregnancy regardless the precise diagnosis after birth. For multiple abnormalities, the screening was considered positive if at least one had been detected prenatally. Fetal anomalies where the ones listed by European surveillance of congenital anomalies; EUROCAT (which excludes some minor abnormalities with very low medical or aesthetic impact).<sup>19</sup>

Cases detected following the first combined test were excluded from the analysis for both costs and efficacy as our aim was to focus on the ultrasound screening programme. However, increased nuchal translucency cases (>99th percentile) were included as these cases are related to the ultrasound screening (high risk for Down's syndrome and other fetal anomalies, whatever the results of maternal biochemical markers). We used data from three French regional registries of birth defects. These public organisations identify cases with congenital anomalies over a predefined area (usually an administrative region). We included three registries: Auvergne, Paris and La Reunion, all members of EUROCAT, the European network for registries of birth defects<sup>20</sup> and using the standards recommended for this purpose. We included the population of women who gave birth (live birth or fetal loss after 20 WG) or following a TOFPA in the areas covered by these three registries, during the study period (2006-2014). We excluded women not resident in those areas. Cost calculations included all procedures performed as part of the screening programme (number of ultrasound screening examinations), further examinations performed following the suspicion of a fetal abnormality and the operating costs of the referral centres. TOPFA costs were not included. We used the public healthcare system perspective and the time horizon of the pregnancy.

Data sources for calculation of costs were as follows:

1. Costs of procedures

The annual number of procedures for the screening and diagnosis of structural fetal anomalies and their costs were extracted from the national claims database, using the Echantillon Généraliste des Bénéficiaires (EGB), a permanent representative sample of 1/97 of the individuals covered by the French Health Insurance System for employees. This public insurance covered 85% of the total population.<sup>21</sup> This claims database is exhaustive and covers the entire French population. The database contains information about procedures' fees (including extra billing (or balance billing)), either performed in free-standing clinics or in hospital facilities, and cost sharing: costs for the healthcare system, both compulsory and complementary health insurance and out-of-pocket costs for patients. After the third month of pregnancy, all healthcare costs (including transportation) are covered by the statutory health insurance, the only out of pocket costs for patients are the extra billing which private practitioners may charge. Each episode of care is identified by a code. We identified pregnant women using delivery codes. Multiple codes are used for ultrasound examinations performed during the pregnancy, depending on the indication. We included procedures related to the detection of fetal anomalies (systematic first, second and third trimester ultrasound examinations, ultrasound examinations for the monitoring of a known fetal anomaly, fetal echocardiography, and amniocentesis, chorionic villus sampling). Procedures unrelated to the prenatal detection of fetal anomalies (dating ultrasound examinations before 11 WG, ultrasound examinations for fetal growth monitoring including Doppler, fetal well-being evaluation) were excluded. We excluded other imaging procedures (MRI or tomodensitometric examination), due to their very low occurrence in the population.

2. Infrastructure costs

In addition to the income resulting from their activity (ultrasound examinations, invasive tests and so on), referral centres in charge of prenatal diagnosis and genetic counselling are funded through a specific governmental grant. The annual amount of this grant was retrieved in official governmental data.<sup>22</sup>

Costs related to the specific screening for Down's syndrome were excluded from the total costs of the programme. Cost of blood tests using maternal biochemical markers were not included, as well as invasive tests performed after a positive first trimester combined test. Costs of the first-trimester ultrasound scan were included in our cost-effectiveness analysis, even if the screening for Down's syndrome was a part of these procedures.

We extrapolated the annual costs of procedures computed from the database to the entire population using the ratio of the total number of annual deliveries (data from the official governmental office for statistics, INSEE<sup>23</sup>) with the annual number of deliveries in the EGB sample. By adding the infrastructure costs, we estimated the total annual costs of the screening programme.

The ACER was estimated in  $\in$  per case detected antenatally, for each year, as follow:

ACER<sub>t</sub>= $C_t/(N_t * R_t * p)$ Where:

- t was the year.
- C were costs of the ultrasound screening programme for birth defects.
- N was the number of deliveries.
- R was the prenatal detection rate for birth defects.
- p was the prevalence of birth defects.

N was extracted from the official governmental office for statistics, INSEE.<sup>23</sup> R and p were estimated from the dataset of the birth defects registers and previously published.<sup>13</sup> p was the average prevalence of birth defects for the study period in the areas covered by the birth defects registers.

In addition to the ACERs, we estimated ICERs by comparing the costs and detection rates from 1 year to the next: ICER<sub>t</sub> =  $(C_t-C_{t-1})/((N_t^* R_t^* p)-(N_{t-1}^* R_{t-1}^* p))$ .

We used a simple linear regression to assess time trends in the costs of ultrasound screening and in the cost-effectiveness ratios. We used logistic regression for looking at trends in the odds of prenatal diagnosis. All analyses were conducted using Stata V.14.0 software (StataCorp, College Station, Texas, USA).

#### RESULTS

In the 1/97 sample of the national claims database, we included a total number of 57 104 pregnant women for the 2006–2014 period, ranging from 5888 to 6882 per year (0.7% to 0.8% of the total number of deliveries in France). The mean maternal age in our sample was similar to that of the national population of pregnant women with the same trend of increase age during the study period (from 29.5 to 29.8 years old).<sup>24</sup> In our sample, the proportion of multiple pregnancies was 1.6% during the study period.

The number of ultrasound screening examinations increased by approximately 20%, from 2.47 per pregnancy in 2006 to 2.98 in 2014 (p=0.005). We observed an increase of all types of ultrasound examinations, especially for the surveillance of fetal anomalies, which increased by three folds during this period (from 0.07 to 0.26 per pregnancy during the study period; p=0.003). The number of fetal echocardiographies increased from 0.01 to 0.03 per pregnancy (p<0.001). The average rate of invasive prenatal diagnosis procedures related to ultrasound screening was 0.016, and this rate did not change significantly over time (p=0.38). This absence of change resulted from two opposite trends: the total number of invasive procedures decreased during the study period (from 0.08 to 0.04 per pregnancy, p<0.001) but the estimated proportion of invasive procedures related to the ultrasound screening progressively increased over time (from 22% to 38% of the total number of invasive tests).

Ultrasound procedures were performed either in the private sector (by self-employed sonographers or in private for profit hospitals) or in public hospitals in 82% and 18%, respectively. Invasive procedures were mostly performed in public hospitals (65% of the total number).

The official fee for screening ultrasound was revised between 2007 and 2008, leading to a 19%, 15% and 27% increase in costs for the first, second and third trimester ultrasound scans, respectively. In addition, the proportion of the first, second and third trimester ultrasound procedures with extra billing increased during the study period from 40.5% to 46.5%, 40.9% to 47.1% and 42.8% to 44.6%, respectively. The average value of extra billing also increased for all ultrasound procedures during the study period. Consequently, the overall ultrasound screening procedures cost progressively increased during the study period from  $\leq$ 139 685 270 in 2006 to  $\leq$ 195 310 309 in 2014 (table 1). Detailed costs for first, second and third trimester screening ultrasound scans are available as online supplementary data.

The specific governmental grant to referral centres was created in 2007, accounting for 6.7% of the total cost of


the French ultrasound screening programme for birth defect between 2006 and 2014
lable 1 Estimated total cost (and its repartition between procedures cost and infrastructure cost) and cost per pregnancy of

	including		
Total cost (€)	Procedures cost (€)	Infrastructure cost(€)	Cost per pregnancy (€)
139 685 270	139 685 270	0	168
147 545 154	137 655 154	9 890 000	180
194 943 053	185 053 053	9 890 000	235
194 453 720	184 563 720	9 890 000	236
196 517 392	186 627 392	9 890 000	236
195 435 422	185 545 422	9 890 000	237
198 731 955	186 161 955	12 570 000	242
203 869 909	188 959 909	14 910 000	251
210 790 309	195 310 309	15 480 000	258
	139 685 270         147 545 154         194 943 053         194 453 720         196 517 392         195 435 422         198 731 955         203 869 909	Total cost (€)         Procedures cost (€)           139 685 270         139 685 270           147 545 154         137 655 154           194 943 053         185 053 053           194 453 720         184 563 720           196 517 392         186 627 392           195 435 422         185 545 422           198 731 955         186 161 955           203 869 909         188 959 909	Total cost (€)Procedures cost (€)Infrastructure cost(€)139 685 270139 685 2700147 545 154137 655 1549 890 000194 943 053185 053 0539 890 000194 453 720184 563 7209 890 000196 517 392186 627 3929 890 000195 435 422185 545 4229 890 000198 731 955186 161 95512 570 000203 869 909188 959 90914 910 000

the screening programme. Due to an increase since 2012, this grant accounted for 7.3% of the total costs in 2014 (table 1).

The overall cost of the screening programme in France was estimated to be  $\leq 210~790~000$ , in 2014. Ultrasound examinations accounted for 99.5% of the total procedural costs (0.5% for invasive procedures). Seventy seven per cent of the total cost was covered by the public health insurance and 23% by patients (out-of-pocket or complementary insurance). Costs per pregnancy, total costs and their distribution are detailed in table 1, for the 2006–2014 period. The cost of screening increased from  $\leq 168$  in 2006 to  $\leq 258$  per pregnancy in 2014 (p=0.001) (figure 1).

We identified 15 989 cases of fetal anomalies (average: 1777 per year (range: 1661–1869)) from the registries between 2006 and 2014. The prevalence of birth defects during the study period was 3.2% and was fairly stable. The overall prenatal detection rate of birth defects following ultrasound screening during the study period was 57.0%, ranging from 53.9% (in 2012) to 58.7% (in 2008). The logistic regression found a small declining trend for the overall prenatal detection rate during the study period (OR=0.985; 95% CI 0.972 to 0.997; p=0.015).



**Figure 1** Chronological evolution of the cost per pregnancy  $(\epsilon)$  of the French ultrasound screening programme for birth defects.

ACER's and ICER's values for the 2006–2014 period are presented in table 2. Prevalence for birth defects was considered as stable during the study period (3.3%). We found a 61% increase in the ACER for ultrasound screening during the study period. ACER increased from  $\in$ 9050 per case detected in 2006 to  $\in$ 14 580 per case detected in 2014 (p=0.001). ICERs had an erratic pattern, with a strong tendency to show that any increment in the cost of screening was highly cost ineffective.

#### DISCUSSION

Our study represents this first analysis of the French prenatal screening programme for structural birth defects (excluding Down's syndrome). We found a trend of decreasing cost-effectiveness from €9050 in 2006 to  $\in$ 14 580 in 2014 (+62%) per case detected. This decrease in efficiency was essentially explained by the increase in costs even if we also found a small decrease in prenatal detection rates. Screening costs per pregnancy increased from €168 in 2006 to €258 in 2014, which was due to an increase in both the number and in the unit costs of ultrasound scans performed for prenatal detection of birth defects. Both the frequency and amounts of extra billing (or balance billing) also increased during the study period. To our knowledge, this is the first study to report on the efficiency of a national ultrasound screening programme for birth defects.

We chose to use both ACERs and ICERs. Indeed, our objective was not to compare the current screening policy to alternatives in order to maximise health benefits but to provide information on how much money is expected to be spent on average per identification of congenital anomaly. The use of ACER allowed simple comparisons from 1 year to another.

We have previously reported the prenatal detection rate of birth defects in France, between 2006 and 2014, using data from regional birth defects registers,<sup>13</sup> all members of EUROCAT, the European network for registries of birth defects.<sup>20</sup> This detection rate was 57.0%,

 Table 2
 Evolution of the average cost-effectiveness ratio (ACER) and incremental cost-effectiveness ratio (ICER) of the French ultrasound screening programme for birth defect between 2006 and 2014, and parameters used for its calculation

	Total costs (€)	Detection rate (%)	Number of deliveries	ACER (€/detected case)	Difference in costs (€)	Difference in detected cases (n)	ICER (€/detected case)
2006	139 685 270	58.2	829 352	9050			
2007	147 545 154	57.9	818 705	9723	7 859 884	-259	Dominated
2008	194 943 053	58.7	828 404	12 518	47 397 899	398	119 111
2009	194 453 720	57.2	824 641	12 886	-489 333	-482	1016
2010	196 517 392	57.2	832 799	12 901	2 063 672	142	14 549
2011	195 435 422	57.8	823 394	12 843	-1 081 970	–16	66 599
2012	198 731 955	53.9	821 047	14 026	3 296 533	-1048	Dominated
2013	203 869 909	57.3	811 510	13 713	5 137 954	699	7355
2014	210 790 309	55.2	818 565	14 580	6 920 400	-409	Dominated

ACERs calculation using the formula:  $ACER_t=C_t/(N_t^*R_t^*p)$ . Where: t was the year, C were costs of the ultrasound screening programme for birth defects (total costs), N was the number of deliveries, R was the prenatal detection rate for birth defects (detection rate), p was the total prevalence of birth defects (p=3.3%, for all the study period). ICERs calculation using the formula:  $ICER_t=(C_t-C_{t-1})/((N_t^*R_t^*p)-(N_{t-1}^*R_{t-1}^*p))$ .

and is covered the cases prenatally detected by ultrasound scans only (other screening modalities such as first trimester combined test with NT<99th were systematically excluded). The logistic regression even found a decreasing trend for the overall prenatal detection rate during the study period (OR=0.985; 95% CI 0.972 to 0.997; p=0.015). In parallel, the costs of the ultrasound screening programme for birth defects sharply increased from €168 in 2006 to €258 in 2014. Several factor could account for the increase in the costs of the ultrasound screening programme. The creation of a governmental grant for the referral centres of prenatal diagnosis in 2007 (and its revaluation since 2012) accounted for 21% of this increase. The official fee for screening ultrasounds was re-evaluated in 2008, which comprised 60% of the increase in costs. The remaining 19% were mostly due to the progressive increase in the number of ultrasound examinations per pregnancy, as well as the increase in extra billing practices. We observed a 51% increase of the total costs of the screening programme, comparatively, the healthcare spending increased by 24% between 2006 and 2014.<sup>25</sup>

As for all screening programmes, prenatal screening for fetal anomalies raises two issues, that is, its relevance and its cost effectiveness. The relevance of ultrasound screening programmes for birth defects is no longer a matter of debate. For certain birth defects, a prenatal diagnosis allows for optimal surveillance of pregnancies and perinatal management, in particular a delivery in an adequate maternity unit to improve postnatal management,<sup>26-30</sup> and for some birth defects, administration of prenatal treatments (eg, fetal surgery).<sup>31 32</sup> Moreover, in cases of severe fetal anomalies, parents may opt for termination of pregnancy, depending on their country's legislation.<sup>33</sup> Our goal was not to present results which could be directly extrapolated to other countries, with different screening programmes or even to countries with a threescan strategy, because the uptake and performance of screening would differ. We suggest, however, that the costeffectiveness of such programmes must be investigated. The number and timing of recommended screening ultrasound scans during pregnancy is the main difference between screening programmes across countries. In Europe, up to three screening ultrasound scans are usually reimbursed to low-risk pregnant women, but some countries recommend one (eg, Denmark, Finland and Sweden), two (eg, England, Belgium and Switzerland) and others three (eg, France, Italy and Spain) scans.<sup>3</sup> In our study, the ultrasounds accounted for the majority of the screening programme costs. Hence differences in the number and fees of ultrasounds can result in substantial differences in the costs of one screening programme from another. In addition, several parameters may impact the number of ultrasound and overall programmes cost, including population coverage, false positive rates and care pathways for positive screenings. Detection rates may also vary from one programme to another. Indeed, several studies have shown significant variations among countries in prenatal detection rates for specific birth defects.<sup>34–37</sup> To our knowledge, only one cost-effectiveness study attempted to compare different programmes of routine antenatal ultrasound screening, by modelling the number and the time of ultrasound screening examinations offered during pregnancy.<sup>10</sup> However, the authors acknowledged that, due to uncertainty about both costs and effectiveness of ultrasound examinations, their model had important limitations.

There are several limitations to our study that should be addressed. First, the methodological choice of ACER is not recommended in economic evaluations. We justified our choice by the absence of a decisional policy context. We complemented the ACERs by an estimate of ICERS, which are not exactly a decision tool since no decision was planned, but rather an observation of how unplanned decisions by professionals resulted in highly ineffective allocation of resources. Second, costs and prenatal detection rates had to be extrapolated from different samples because nationwide data are not available in France. However, we do not believe that this difference between our study populations could have biased our results. Thus, prenatal diagnosis practices and policies are decided at a national level. Moreover, referral centres for prenatal diagnosis are equitably distributed across the country. Third, due to a modification in the calculation of the hospital's funding between 2006 and 2009, the number of ultrasound examinations performed during this period in public hospitals was not recorded and had to be estimated. However, when we applied our estimation method on the 2010-2014 period and compared the estimated total costs to the real total cost (computed with the database), we noticed only small differences (between -2.7% and +0.8% depending on the year). In addition, public hospitals accounted for less than 20% of all ultrasound examinations performed, thus limiting a potential bias resulting from the estimation. Fourth, some inputs related to the screening were not included in the costs estimation. Some procedures indicated after a positive screening (fetal MRI and fetal treatment) do not have specific codes and could therefore not be identified. Consequently, our global cost estimation is slightly underestimated. Nevertheless, according to the French Agency of Biomedecine reports, such procedures are performed infrequently and the related cost should be insignificant.<sup>38</sup>

Fifth, the ultrasound prenatal screening not only focuses on the detection of fetal anomalies. Thus, other complications such as multiple gestation, placenta praevia or fetal growth anomalies might be found and contribute to the overall benefit of the screening. Some of these anomalies are more severe than others and their detection will radically change the management of the pregnancy. Our data does not allow identification these cases and therefore a precise quantification of the potential benefits in relation to costs. Sixth, we did not include the costs of subsequent decisions following the detection of birth defects, as we did not want to assume that the objective of the screening programme was to increase the number of terminations or to reduce the costs associated with postnatal care. And finally, although not specifically monitored, the increase in ultrasound scans is likely to increase non healthcare costs to women, with additional travel cost, time costs and missed days of work.

#### CONCLUSION

In France, between 2006 and 2014, the increase in costs of the ultrasound screening for birth defects was not associated to an increase in its efficacy. The observational design of our study limits the interpretation of the observed trends, especially for the increase in costs, which may be partly justified. Official fees for screening ultrasounds need to be revaluated to obtain fair pricing. However, we observed a clear diminishing returns for costs associated with prenatal ultrasound screening of birth defects, in France. An international comparison of

ultrasound screening programmes for birth defects could be conducted if similar studies were performed in other countries.

#### Author affiliations

<sup>1</sup>Fetal Medecine Department, Armand Trousseau Hospital, AP-HP, Sorbonne University, Paris, UK

<sup>2</sup>Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), DHU Risks in Pregnancy, INSERM UMR 1153, Center for Epidemiology and Statistics, Sorbonne Paris Cité (CRESS), Paris Descartes University, Paris, France <sup>3</sup>Medical genetics, Reunion Registry of Congenital Anomalies, St Pierre, Saint Pierre de la Réunion, France

<sup>4</sup>Medical genetics, Study Center for Congenital Anomalies, CEMC-Auvergne, Clermont-Ferrand, France

<sup>5</sup>Fetal Medicine Department, Hopital Armand-Trousseau, Paris, France
<sup>6</sup>AP-HP Health economics research unit & Department of Public Health, Henri Mondor Hospital, CRESS-UMR1153 - INSERM & UPEC, Paris, France

Acknowledgements Authors express their gratitude to the team of the birth defect registers which participate to the study and to the reviewers for their very constructive and insightful comments.

**Contributors** CF, BK, J-MJ and ID-Z conceptualised the study and designed the analysis. FD was certified for the EGB database access. CF, FD, BK, HR and IP collected the data. All authors contributed to perform the analysis. CF, FD, BK, J-MJ and ID-Z wrote the final manuscript. J-MJ and ID-Z were the guarantor of the study.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval It was a time-trend observation on aggregated data, provided by an analysis on anonymised individual data, and didn't require ethical approval. The EGB analysis, part of the SNIIRAM and property of the CNAMTS, was performed after INSERM approval and is covered by the Commission Nationale de l'Informatique et des Libertés (CNIL) (accords CNIL AT/CPZ/SVT/JB/DP/CR052220 du 14/06/2005 et DP/CR071761 du 28/08/2007).

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID** iDs

Babak Khoshnood http://orcid.org/0000-0002-4031-4915 Jean-Marie Jouannic http://orcid.org/0000-0002-7890-3790

#### REFERENCES

- Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? health economics and the presidential candidates. N Engl J Med 2008;358:661–3.
- Russell LB. The role of prevention in health reform. N Engl J Med 1993;329:352–4.
- 3 EUROCAT Central Registry. *EUROCAT special report: prenatal* screening policies in Europe 2010. University of Ulster, 2010.
- 4 Lee K, Khoshnood B, Chen L, et al. Infant mortality from congenital malformations in the United States, 1970-1997. Obstet Gynecol 2001;98:620–7.
- 5 Hatton F, Bouvier-Colle MH, Blondel B, et al. [Trends in infant mortality in France: frequency and causes from 1950 to 1997]. Arch Pediatr 2000;7:489–500.

## 

- 6 Matthews TJ, MacDorman MF, Thoma ME. Infant mortality statistics from the 2013 period linked Birth/Infant death data set. *Natl Vital Stat Rep* 2015;64:1–30.
- 7 Ferrier C, Dhombres F, Guilbaud L, et al. [Ultrasound screening for birth defects: A medico-economic review]. Gynecol Obstet Fertil Senol 2017;45:408–15.
- 8 Roberts T, Henderson J, Mugford M, *et al*. Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness. *BJOG* 2002;109:44–56.
- 9 Vanara F, Bergeretti F, Gaglioti P, *et al.* Economic evaluation of ultrasound screening options for structural fetal malformations. *Ultrasound Obstet Gynecol* 2004;24:633–9.
- 10 Roberts T, Mugford M, Piercy J. Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach. *Br J Obstet Gynaecol* 1998;105:960–70.
- 11 Long G, Sprigg A. A comparative study of routine versus selective fetal anomaly ultrasound scanning. *J Med Screen* 1998;5:6–10.
- 12 Leivo T, Tuominen R, Saari-Kemppainen A, et al. Cost-Effectiveness of one-stage ultrasound screening in pregnancy: a report from the Helsinki ultrasound trial. Ultrasound Obstet Gynecol 1996;7:309–14.
- 13 Ferrier C, Dhombres F, Khoshnood B, *et al.* Trends in resource use and effectiveness of ultrasound detection of fetal structural anomalies in France: a multiple registry-based study. *BMJ Open* 2019;9:e025482.
- 14 Khoshnood B, Lelong N, Lecourbe A, et al. Registre des malformations congénitales de Paris. Surveillance épidémiologique et diagnostic prénatal des malformations : évolution sur 35 ans (1981-2014), 2014.
- 15 Sureau C, Henrion R. Rapport du comité national technique de l'échographie de dépistage prénatal, 2005. Available: https://www. cfef.org/archives/lettres/DocusCTE/rapportCTE.pdf
- 16 Viossat P, Ville Y, Bessis R, et al. [Report of the French Comité national technique de l'échographie de dépistage prénatal (CNTEDP)--Recommendations for second line prenatal ultrasound]. Gynecol Obstet Fertil 2014;42:51–60.
- 17 LOI no 2001-588 du 4 juillet 2001 relative l'interruption volontaire de grossesse et la contraception. Available: http://admi.net/jo/ 20010707/MESX0000140L.html [Accessed 18 Apr 2019].
- 18 Arrêté Du 23 juin 2009 fixant les règles de bonnes pratiques en matière de dépistage et de diagnostic prénatals avec utilisation des marqueurs sériques maternels de la trisomie 21. Available: https://www.legifrance.gouv.fr/affichTexte.do?cidTexte= JORFTEXT000020814373 [Accessed 18 Jun 2019].
- 19 EUROCAT. EUROCAT subgroups of congenital anomalies, version 2014, 2014.
- 20 Boyd PA, Haeusler M, Barisic I, et al. Paper 1: The EUROCAT network--organization and processes. Birth Defects Res A Clin Mol Teratol 2011;91 Suppl 1:S2–15.
- 21 Bezin J, Duong M, Lassalle R, et al. The National healthcare system claims databases in France, SNIIRAM and EGb: powerful

tools for pharmacoepidemiology. *Pharmacoepidemiol Drug Saf* 2017;26:954–62.

- 22 Agency for hospitals information (ATIH). Available: https://www.atih. sante.fr/dotations-annuelles-migac-et-fir
- 23 French national Institue of statistics and economic studies (INSEE). Available: https://www.insee.fr/fr/statistiques/2381380
- 24 French National Institue of Statistics and Economic Studies (INSEE). Average age of mothers at birth. Available: https://www.insee.fr/fr/ statistiques/2381390#tableau-Donnes [Accessed 19 Jun 2019].
- 25 L'évolution de la CSBM depuis 1950. Available: https://drees. solidarites-sante.gouv.fr/IMG/pdf/fiche2-7.pdf [Accessed 25 May 2019].
- 26 Bonnet D, Coltri A, Butera G, et al. Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality. *Circulation* 1999;99:916–8.
- 27 Tworetzky W, McElhinney DB, Reddy VM, et al. Improved surgical outcome after fetal diagnosis of hypoplastic left heart syndrome. *Circulation* 2001;103:1269–73.
- 28 Franklin O, Burch M, Manning N, et al. Prenatal diagnosis of coarctation of the aorta improves survival and reduces morbidity. *Heart* 2002;87:67–9.
- 29 Wilson RD, Sogc Genetics CommitteeSpecial Contributor, . Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. *J Obstet Gynaecol Can* 2014;36:927–39.
- 30 Yamamura Y, Swartout JP, Anderson EA, et al. Management of mild fetal pyelectasis: a comparative analysis. J Ultrasound Med 2007;26:1539–43.
- 31 Morris RK, Malin GL, Quinlan-Jones E, *et al.* The percutaneous shunting in lower urinary tract obstruction (PLUTO) study and randomised controlled trial: evaluation of the effectiveness, cost-effectiveness and acceptability of percutaneous vesicoamniotic shunting for lower urinary tract obstruction. *Health Technol Assess* 2013;17:1–232.
- 32 Adzick NS, Thom EA, Spong CY, *et al*. A randomized trial of prenatal versus postnatal repair of myelomeningocele. *N Engl J Med* 2011;364:993–1004.
- 33 Gissler M, Fronteira I, Jahn A, *et al.* Terminations of pregnancy in the European Union. *BJOG* 2012;119:324–32.
- 34 Garne E, Loane M, Wellesley D, *et al.* Congenital hydronephrosis: prenatal diagnosis and epidemiology in Europe. *J Pediatr Urol* 2009;5:47–52.
- 35 Pedersen RN, Calzolari E, Husby S, *et al.* Oesophageal atresia: prevalence, prenatal diagnosis and associated anomalies in 23 European regions. *Arch Dis Child* 2012;97:227–32.
- 36 Garne E, Eurocat Working Group. Prenatal diagnosis of six major cardiac malformations in Europe--a population based study. Acta Obstet Gynecol Scand 2001;80:224–8.
- 37 Boyd PA, Loane M, Garne E, et al. Sex chromosome trisomies in Europe: prevalence, prenatal detection and outcome of pregnancy. Eur J Hum Genet 2011;19:231–4.
- 38 Agence biomédecine. Diagnostic prénatal 2014, 2015.